Loading
Gastrointestinal oncologist who led landmark trials of perioperative chemotherapy in gastric and oesophageal cancer.
David Cunningham is a consultant medical oncologist and Director of Clinical Research at The Royal Marsden. His specialisms are gastrointestinal oncology, oesophago-gastric cancer and colorectal cancer. He led the MAGIC trial of perioperative chemotherapy in gastric cancer, reported in the New England Journal of Medicine as perioperative chemotherapy versus surgery alone for resectable gastro-oesophageal cancer, and the REAL-2 trial. He has directed clinical research at the Royal Marsden across gastric and gastro-oesophageal junction, oesophageal and colorectal cancers. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer (MAGIC) | NEJM | 2006 |
| CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer | New England Journal of Medicine | 2023 |
Shares The Royal Marsden, Colorectal cancer.
Shares The Royal Marsden, Colorectal cancer.
Shares The Royal Marsden, Colorectal cancer.
Shares CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer, Colorectal cancer.
Shares CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer, Colorectal cancer.
Shares CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer, Colorectal cancer.
Shares The Royal Marsden, Colorectal cancer.
Shares CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/